Biosimilars market is expected to be worth $19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014.

Dallas, TX -- (ReleaseWire) -- 10/30/2013 --According to a new market research report, ‘Global biosimilars Market (2009 - 2014)’, published by MarketsandMarkets (www.marketsandmarkets.com), the global biosimilars market is expected to be worth US$19.4 billion by 2014, recording a CAGR of 89.1% from 2009 to 2014. The increasing demand from patients, insurers, and government agencies to reduce the costs of blockbuster biopharmaceuticals has created numerous opportunities in the global biosimilars market.

Browse more than 60 market data tables and in-depth TOC on biosimilars market.

http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

Early buyers will receive 10% customization on this report.

Recombinant non-glycosylated proteins form the largest segment in biosimilars market, with an estimated $11.5 billion by 2014. This market has a high CAGR of 87.9% from 2009 to 2014 mainly because most of the branded blockbuster biopharmaceutical drugs such as interferon, human growth hormone (Somatropin), insulin and G-CSF, belong to this class and have wide range of applications.

Currently, the biosimilars market is highly fragmented and its huge opportunities are attracting new players. Favourable regulatory developments in the biosimilars sector are expected to increase the market share and profit margins while reducing medical expenditure.

Asia’s early commercialization and high absorption rate of biosimilars products made it the dominant market in 2008 with 34.1% share of the global biosimilars product market. The American market (including North America and Latin America) is expected to account for nearly 35.3% of the total revenues in 2014. The European market is also gaining momentum after the approval of its first biosimilars Omnitrope in 2006.

Scope of the Report

This report aims to identify and analyze biosimilars market on the basis of products, services, technology, and applications.

Browse Related Reports:
European Injectable Drug Delivery Market By Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Forecasts to 2017
http://www.marketsandmarkets.com/Market-Reports/european-injectable-drug-delivery-market-1205.html

Active Pharmaceutical Ingredient (API) Market Trends, Competitive Landscape and Global Forecasts (2011-2016)
http://www.marketsandmarkets.com/Market-Reports/API-Market-263.html

About MarketsandMarkets
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://www.mnmblog.org
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets